David W. Schulz - Concepedia

Author

David W. Schulz

Also Known As

D Schulz, D W Schulz, D. Schulz, D. W. SCHULZ, D. W. Schulz, D.W. Schulz, DAVID W. SCHULZ, David W Schulz, David W. Schulz

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)University of North Carolina at Chapel Hill Emory University Harvard University

About

David W. Schulz is an author at Pfizer (United States) specializing in medicine, pharmacology, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	22	2.3K
2	Social Sciences	10	11	1K
3	Natural Sciences	3	3	199
4	Public Health	3	3	672
5	Health Sciences	2	2	336

David W. Schulz

Publications

4.2K

Citations

H-Index

Page 1

	Year	Citations
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation Jotham W. Coe, Paige R. Brooks, Michael G. Vetelino, Journal of Medicinal Chemistry	2005	929
Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid Hans Rollema, Leslie K. Chambers, J.W. Coe, Neuropharmacology Tobacco CessationMolecular PharmacologyTobacco ControlMedicineNicotine	2006	532
CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. David W. Schulz, Robert S. Mansbach, Jeffrey Sprouse, Proceedings of the National Academy of Sciences Social SciencesMolecular PharmacologyCrf ReceptorsNeuroimmunologyNeurochemistry	1996	378
Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Thomas Seeger, P A Seymour, Anne W. Schmidt, Journal of Pharmacology and Experimental Therapeutics	1995	320
Barbiturate enhancement of GABA-mediated inhibition and activation of chloride ion conductance: correlation with anticonvulsant and anesthetic actions David W. Schulz, Robert L. Macdonald Brain Research Chloride Ion ConductanceBarbiturate EnhancementNeurophysiologyMedicinePhysiology	1981	203
3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1*) agonist and rotationally restricted phenolic analog of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole John E. Macor, Catherine A. Burkhart, James Heym, Journal of Medicinal Chemistry	1990	160
SCH-23390: A selective D1 dopamine antagonist with potent D2 behavioral actions Richard B. Mailman, David W. Schulz, Mark H. Lewis, European Journal of Pharmacology Molecular PharmacologyPsychoactive DrugBehavioral NeuroscienceAddictionMedicine	1984	158
Glucose 1,6-Diphosphate Formation by Phosphoglucomutase in Mammalian Tissues Janet V. Passonneau, O. H. Lowry, David W. Schulz, Journal of Biological Chemistry GlycobiologyCellular PhysiologyInsulin SignalingMouse MuscleMetabolic State	1969	133
Cochicine-induced granule cell loss in rat hippocampus: Selective behavioral and histological alterations Thomas J. Walsh, David W. Schulz, Hugh A. Tilson, Brain Research Rat HippocampusDevelopmental BiologyNeurophysiologyBehavioral NeuroscienceSelective Behavioral	1986	119
Binding of [<sup>3</sup>H]SCH23390 in Rat Brain: Regional Distribution and Effects of Assay Conditions and GTP Suggest Interactions at a D<sub>1</sub>‐Like Dopamine Receptor David W. Schulz, Edward J. Stanford, Stephen W. Wyrick, Journal of Neurochemistry	1985	117

Page 1